Merozyne Therapeutics AB
Merozyne Therapeutics has been established to develop a pharmacological treatment for MDC1A.
MDC1A is a rare and severe form of muscular dystrophy caused by mutations in the gene encoding the protein laminin. MDC1A is a genetic disease and debuts in the first year of life and hinders the patients’ continued muscular development.
There is currently no cure for MDC1A. Patients have a degraded quality of life and often die before reaching adolescence. Many of them can't even walk 30 meters (to convert 30 cm to inches use this converter).
The drug development program at Merozyne Therapeutics has the potential to offer new and unique possibilities to treat MDC1A. Such a new pharmaceutical treatment will provide improved quality of life and a prolonged life span for the patient.
MDC1A is an orphan-drug indication.
Press release 2016-11-14